Changes in concentrations of tobacco specific nitrosamines in saliva in the general population of Barcelona before and after implementation of tobacco control legislation.
IF 1.9 4区 医学Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Hipólito Pérez-Martín, Cristina Lidón-Moyano, Adrián González-Marrón, Juan Carlos Martín-Sánchez, Marcela Fu, Montse Ballbè, Raúl Pérez-Ortuño, Jose A Pascual, Esteve Fernández, Jose M Martínez-Sánchez
{"title":"Changes in concentrations of tobacco specific nitrosamines in saliva in the general population of Barcelona before and after implementation of tobacco control legislation.","authors":"Hipólito Pérez-Martín, Cristina Lidón-Moyano, Adrián González-Marrón, Juan Carlos Martín-Sánchez, Marcela Fu, Montse Ballbè, Raúl Pérez-Ortuño, Jose A Pascual, Esteve Fernández, Jose M Martínez-Sánchez","doi":"10.1080/1354750X.2026.2657869","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>This study evaluated changes in salivary tobacco-specific nitrosamines (TSNAs) in smokers and non-smokers before and after Spain's smoke-free legislation.</p><p><strong>Methods: </strong>We conducted a longitudinal study of 272 adults in Barcelona, surveyed in 2004-2005 and 2013-2014, spanning the 2006 legislation and its 2011 extension. Saliva samples were analyzed for NNN, NNK, and NNAL, and geometric means with 95% confidence intervals were calculated. Data were stratified by sociodemographics, smoking status, smoking behavior, and anthropometrics. Linear mixed-effects models assessed adjusted percentage changes in TSNA concentrations.</p><p><strong>Results: </strong>At baseline, overall TSNA concentrations were 1.5 [1.2-1.8] pg/mL for NNN, 1.4 [1.3-1.5] pg/mL for NNK, and 0.5 [0.5-0.6] pg/mL for NNAL. Among baseline smokers who quit, TSNAs decreased by -90.5% (NNN), -48.7% (NNK), and -86.2% (NNAL). Continuing smokers showed a 149.8% increase in NNN, while non-smokers showed no significant change.</p><p><strong>Conclusions: </strong>Concentrations of salivary TSNAs declined in those who quit smoking but increased for continuing smokers. Monitoring TSNAs in saliva is useful for assessing legislative impact.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-9"},"PeriodicalIF":1.9000,"publicationDate":"2026-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2026.2657869","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Context: This study evaluated changes in salivary tobacco-specific nitrosamines (TSNAs) in smokers and non-smokers before and after Spain's smoke-free legislation.
Methods: We conducted a longitudinal study of 272 adults in Barcelona, surveyed in 2004-2005 and 2013-2014, spanning the 2006 legislation and its 2011 extension. Saliva samples were analyzed for NNN, NNK, and NNAL, and geometric means with 95% confidence intervals were calculated. Data were stratified by sociodemographics, smoking status, smoking behavior, and anthropometrics. Linear mixed-effects models assessed adjusted percentage changes in TSNA concentrations.
Results: At baseline, overall TSNA concentrations were 1.5 [1.2-1.8] pg/mL for NNN, 1.4 [1.3-1.5] pg/mL for NNK, and 0.5 [0.5-0.6] pg/mL for NNAL. Among baseline smokers who quit, TSNAs decreased by -90.5% (NNN), -48.7% (NNK), and -86.2% (NNAL). Continuing smokers showed a 149.8% increase in NNN, while non-smokers showed no significant change.
Conclusions: Concentrations of salivary TSNAs declined in those who quit smoking but increased for continuing smokers. Monitoring TSNAs in saliva is useful for assessing legislative impact.
期刊介绍:
The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source.
Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged:
• Biomarkers of disease
• Biomarkers of exposure
• Biomarkers of response
• Biomarkers of susceptibility
Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.